4.7 Review

Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence

Journal

JOURNAL OF MEDICAL VIROLOGY
Volume 93, Issue 5, Pages 2675-2682

Publisher

WILEY
DOI: 10.1002/jmv.26727

Keywords

coronavirus; COVID-19; intravenous immune globulin; IVIG therapy; viral infection

Categories

Funding

  1. Iran University of Medical Sciences, Tehran, Iran

Ask authors/readers for more resources

Since the end of 2019, a special pneumonia associated with a novel coronavirus named 2019-nCoV has been reported in Wuhan, China. Currently, there is no definitive treatment for coronavirus disease-19 (COVID-19) infection, and drugs introduced are still in the clinical trial phase.
Since December 31, 2019, unknown causes of pneumonia have been reported in Wuhan, China. This special pneumonia associated with a novel coronavirus was named 2019-nCoV by the World Health Organization (WHO) in January 2020. From the beginning of this infectious disease, clinicians and researchers have been endeavoring to discover an effective and suitable treatment for affected patients. To date, there is no definitive and specific treatments for coronavirus disease-19 (COVID-19) infection while drugs introduced are still in the clinical trial phase. Intravenous immune globulin (IVIG) is a biological product prepared from the serum and an optional treatment for patients with antibody deficiencies. In many countries, much attention has been paid to the use of IVIG in the treatment of patients with COVID-19. Due to the therapeutic importance of IVIG in virus infections, in the current study, we reviewed the possible effect of IVIG in viral infections and potential evidence of IVIG therapy in patients with COVID-19 virus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available